S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support

Cabaletta Bio (CABA) Stock Price, News & Analysis

$22.88
-0.17 (-0.74%)
(As of 02/29/2024 ET)
Today's Range
$22.56
$24.04
50-Day Range
$19.48
$25.38
52-Week Range
$5.88
$26.35
Volume
685,314 shs
Average Volume
835,833 shs
Market Capitalization
$980.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.27

Cabaletta Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
27.9% Upside
$29.27 Price Target
Short Interest
Bearish
15.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Cabaletta Bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$456,280 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.59) to ($1.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

757th out of 957 stocks

Biological Products, Except Diagnostic Industry

125th out of 160 stocks


CABA stock logo

About Cabaletta Bio Stock (NASDAQ:CABA)

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Stock Price History

CABA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CABA Mar 2024 35.000 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
CABA Mar 2024 30.000 call
Cabaletta Bio Inc Ordinary Shares
Buy Cabaletta Bio's Promising SLE Treatment
Cabaletta Bio, Inc. (CABA)
See More Headlines
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2021
Today
3/01/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.27
High Stock Price Target
$50.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+27.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-52,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.60 per share

Miscellaneous

Free Float
37,566,000
Market Cap
$980.41 million
Optionable
Optionable
Beta
2.47
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Steven A. Nichtberger M.D. (Age 63)
    Co-Founder, Chairman, CEO & President
    Comp: $970.6k
  • Dr. Gwendolyn K. Binder Ph.D. (Age 49)
    President of Science & Technology
    Comp: $692.99k
  • Dr. David J. Chang FACR (Age 61)
    M.D., M.P.H., Chief Medical Officer
    Comp: $676.74k
  • Dr. Michael C. Milone M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. Anup Marda M.B.A. (Age 47)
    Chief Financial Officer
    Comp: $548.2k
  • Dr. Samik Basu M.D.
    Chief Scientific Officer
  • Mr. Michael Gerard J.D. (Age 44)
    General Counsel & Secretary
  • Ms. Heather Harte-Hall M.Sc.
    Chief Compliance Officer
  • Ms. Martha O'Connor
    Chief Human Resources Officer














CABA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings
or view top-rated stocks.

What is Cabaletta Bio's stock price target for 2024?

11 Wall Street analysts have issued 12 month price objectives for Cabaletta Bio's stock. Their CABA share price targets range from $10.00 to $50.00. On average, they expect the company's stock price to reach $29.27 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for CABA
or view top-rated stocks among Wall Street analysts.

How have CABA shares performed in 2024?

Cabaletta Bio's stock was trading at $22.70 at the beginning of 2024. Since then, CABA stock has increased by 0.8% and is now trading at $22.88.
View the best growth stocks for 2024 here
.

Are investors shorting Cabaletta Bio?

Cabaletta Bio saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 6,830,000 shares, an increase of 6.9% from the January 31st total of 6,390,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 5.4 days.
View Cabaletta Bio's Short Interest
.

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CABA earnings forecast
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) posted its quarterly earnings data on Sunday, October, 31st. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.98%), Perceptive Advisors LLC (4.67%), Commodore Capital LP (4.43%), Jennison Associates LLC (3.80%), Price T Rowe Associates Inc. MD (1.23%) and Price T Rowe Associates Inc. MD (1.23%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends
.

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CABA) was last updated on 3/1/2024 by MarketBeat.com Staff